Benitec Reports Positive Interim BB-301 Phase 1b/2a Results
Benitec Biopharma reported positive interim Phase 1b/2a results for high-dose BB-301 and continued durable improvements for low-dose BB-301.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Benitec Reports Positive Interim Phase 1b/2a Results for High-Dose BB-301
The company also reported continued durable improvements for low-dose BB-301.